Polarean Imaging welcomes Bill Blair to its Board as Non-Executive Director

– USA, NC –  Polarean Imaging plc (LON: POLX), a commercial-stage medical device leader in advanced magnetic resonance imaging of the lungs, today announced the appointment of Bill Blair to its Board as an Independent Non-Executive Director with immediate effect.

“We are delighted to welcome Bill to the Board of Polarean. We felt it was important to have someone with further experience in the UK healthcare sector and with AIM-listed companies on the Board. Following conversations with Amati Global Investors, our largest shareholder, and several other shareholders, we identified Bill as the ideal candidate, given his deep understanding of the UK investor landscape and vast experience with AIM,” said CEO, Dr. Christopher von Jako. “We believe Bill’s expertise will be invaluable to us as we continue the commercialization of XENOVIEW and look to address the unmet medical needs of patients suffering from chronic respiratory diseases. As a team, we look forward to his strategic advice helping us identify and evaluate the various financing options for the Company.”

About William Blair

Bill Blair is an investment professional, board director, and executive with over 30 years of experience in investment banking, fund management, venture capital, and private equity, with particular expertise in advising smaller and AIM-listed healthcare companies.

He currently serves as a NED and Chair of the Audit Committee at North East Finance, which invested £160m in a portfolio of companies ranging from micro-companies to those now listed on the London Stock Exchange in the North East of England and the Tees Valley. Since July 2020, Bill has also served as a NED for Iksuda Therapeutics, a biotechnology company focused on developing antibody-drug-conjugate therapies, providing strategic advice and support on funding options and exit strategy. Bill is also currently a director at HVS Advisers, providing strategic advice to venture capital funds, institutions, and SMEs (small and medium enterprises), and is a member of the Investment Advisory Board at the Pioneer Group Life Sciences Fund.

Bill Blair said: “I am pleased to be joining the Board of Polarean and to be able to share my experience as an investment professional and adviser to innovative companies. I am excited by Polarean’s technology and its potential in both pulmonary and cardio-pulmonary medicine, and look forward to working with the other Board members to take the Company forward.”

About Polarean

The Company and its wholly owned subsidiary, Polarean, Inc. are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionize pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung ventilation, diagnose disease, characterize disease progression, and monitor response to treatment. By researching, developing, and commercializing novel imaging solutions with a non-invasive and radiation-free functional imaging platform. Polarean’s vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised MRI contrast agent to be approved in the United States. The company also commercializes systems, and FDA-cleared post-processing software (to support ventilation defect analysis), to support fully integrated modern respiratory imaging operations.

SOURCE: https://polarean.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.